BioAdaptives Inc (BDPT)

[powerbattles]

They developed a new website. I can no longer purchase this product called PluriPain. Does anyone here know where I can find this amazing PluriPain?

[mars2063]

????? Dilution??? As 2 bill?
Fake society!

[mars2063]

News ?????????

[DK11]

That would be nice, I was just expecting this New Management to do a little more. At least say something.

[WorkinGreen]

Good. Havn’t forgot about it enough to let me get my damn .0001s yet tho

[DK11]

wow 39 volume' looks like everyone has forgot about this failure

[carusso]

Hear, hear!

[awesomed007]

Good, this stock needs some serious help. Investors not happy about stock’s performance, straight up awful.

[unvctrader9m]

Either this guy is out of his mind to join BDPT or they have something really special we don’t know about it yet!
Wait game!
At least no dilution for a while now

[MC10459]

https://menafn.com/1108279173/Investornewsbreaks-Bioadaptives-Inc-BDPT-Appoints-Car-Rental-Industry-Veteran-To-Its-Board-Of-Directors

[DK11]

Hopefully it only gets better from now on.

[stervc]

BDPT Welcomes Gimhana Dissanayake to Its Board of Directors...

This is more solid news for BDPT as a guy of this caliber would not be joining this team for something small in my opinion:

https://www.otcmarkets.com/stock/BDPT/news/story?e&id=2876656
BioAdaptives, Inc. Welcomes Gimhana Dissanayake to Its Board of Directors.

We are confident that Gimhana’s leadership will significantly enrich our board’s talent and expertise, propelling us to new heights.

LAS VEGAS, May 30, 2024 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a leader in the health and wellness sector, today announces the appointment of Gimhana Dissanayake to its Board of Directors. Gimhana, who currently serves as the vice president of operational sales for North America at The Hertz Corporation (NYSE: HTZ), brings over two decades of comprehensive experience and a proven track record of strategic growth and operational excellence to BioAdaptives.

With an illustrious career that has spanned various leadership roles at Hertz, Gimhana is renowned for his strategic vision and leadership acumen. He has been instrumental in advancing the Hertz, Dollar and Thrifty brands, significantly enhancing their market presence and competitive edge. As the senior director of strategic partnerships, he spearheaded initiatives that fostered key alliances with Fortune 500 companies and drove substantial growth across 10 revenue verticals for North America. His efforts earned him the nickname “Founder of Canada” within Hertz, a testament to his successful expansion of the company’s market share in the region. His strategic prowess is a valuable asset that will undoubtedly benefit BioAdaptives.

Gimhana's educational background and extensive professional experience make him an invaluable addition to the BioAdaptives board. He holds an undergraduate degree from Oklahoma State University and an MBA from California State University, Sacramento. In addition, he has completed advanced executive education at Cornell University and the Wharton School of Business. This rich academic and professional foundation equips him with the knowledge and skills necessary to significantly contribute to Bioadaptive's growth and success.

“We are delighted to welcome Gimhana to our Board of Directors,” said Jim Keener, chairman of the board at BioAdaptives. “His exceptional contributions to the car rental industry and his strategic insight are precisely what BioAdaptives needs as we continue to innovate and expand our reach in the wellness sector. We are confident that Gimhana’s leadership will significantly enrich our board’s talent and expertise, propelling us to new heights.”

About BioAdaptives

BioAdaptives, Inc. develops and distributes natural herbal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; stress resistance; endurance; recovery from injury, illness, and exercise; and anti-aging properties. Our current dietary supplement formulations are carefully selected from the best sources worldwide, and proprietary methods are utilized to enhance the bioavailability of nutrients. Our products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, pain relief and improved appearance.

BioAdaptives' common shares trade in the OTC market under the symbol BDPT. None of the statements about our products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Additional information can be found at www.shopbioadaptives.com or in our SEC filings.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release, including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the press release date, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date after the date of this press release.

Contact

Investor Relations
BioAdaptives, Inc.
[phone]
[e-mail]

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[e-mail]

v/r
Sterling

[MC10459]

https://www.investorwire.com/newsarticle/?qmstory=5266682648393905

[MC10459]

https://www.streetinsider.com/dr/news.php?id=23300472&gfv=1

[Dark Roast]

lol. You mean the new story to lure the sheep in? Hahaha.

[mars2063]

Bad bad bad 👎👎👎

[DK11]

More possible now then before

[carusso]

Great. Can we get out of trips now?

[Ribo]

8k, James Keener as new CEO.
https://ih.advfn.com/stock-market/USOTC/bioadaptives-pk-BDPT/stock-news/93904851/form-8-k-current-report

[DK11]

This new CEO James Keener, hopefully can bring in some institutional investors and more Capital possibly through his connections. will see

[Ribo]

James Keener, recently appointed as the Chief Executive Officer of BioAdaptives, Inc., BDPT, brings a wealth of experience spanning nearly three decades. His entrepreneurial journey has traversed various sectors, including real estate, agricultural science, hospitality, construction, and maintenance systems, equipping him with a multifaceted perspective on business and innovation.

As a dynamic leader, Keener has earned a sterling reputation for cultivating a culture of productivity and enthusiasm among stakeholders, consistently delivering exceptional outcomes. He is particularly noted for his role as a turnaround specialist, adept at transforming underperforming ventures into profitable enterprises.

Before his tenure at BioAdaptives, Keener honed his strategic acumen first as a consultant and subsequently as the CEO of a family office investment fund. There, he skillfully managed diversified holdings in real estate, business investment, agriculture, retail, and internet marketing, proving his ability to oversee and expand complex portfolios effectively.

Keener's entrepreneurial prowess is best demonstrated by the specialized construction and maintenance company he founded, which, under his guidance, achieved remarkable growth. It was acknowledged as the fastest-growing company in all sectors across the Hawaiian islands in 2019 and continued its upward trajectory into 2020.

In his new role at BioAdaptives, Keener is poised to leverage his extensive experience in operational transformation to drive innovation and growth within the advanced nutrition and wellness solutions sector. His leadership comes at a crucial juncture for the company, which is on the brink of expanding its influence in the market of high-quality wellness and nutritional products, catering to a diverse range of consumer needs, including both human and animal health.

Under Keener’s guidance, BioAdaptives is set to redefine industry standards by elevating the research and development of nutritional solutions, thereby enhancing health and wellness globally. He officially assumed his role as CEO on May 21, 2024, and is unwavering in his commitment to expanding BioAdaptives' product offerings and market presence, while nurturing a team of exceptional talent.
https://www.shopbioadaptives.com/pages/investors

[pinkslipjunkie]

Oh Oh...the scientist bailed.

[Penny2Dime]

Day1!

[DK11]

This is good news that finally got rid of the old ducks.

[WorkinGreen]

“BioAdaptives, Inc. Appoints James Keener as New CEO to Lead Strategic Growth Initiatives

LAS VEGAS, NV - (NewMediaWire) - May 21, 2024 - BioAdaptives, Inc. (OTC: BDPT), a pioneer in advanced nutrition and wellness solutions, announced a significant addition to its Executive Team today. James Keener has been appointed the new CEO and will play a pivotal role in driving the company's strategic initiatives and fostering continued growth.

BioAdaptives announced today that James Keener, a seasoned marketing and turnaround innovative executive, had taken over as the new Chief Executive Officer and Chairman of the Board of the Company. Among his various endeavors, Mr Keener brings a wealth of experience and expertise to BioAdaptives. He has led a specialized construction and maintenance company to become the fastest-growing company in Hawaii for 2019/2020, a testament to his ability to drive growth. He has also successfully turned around a private investment company with diverse real estate, agriculture, retail, and Internet marketing holdings, demonstrating his strategic thinking and leadership. Mr. Keener's past successes instill optimism for BioAdaptives' future and underline his potential to drive the Company's growth.

Dr. Edward Jacobs, former CEO, said, "After personally devoting a decade to discovery and product development at BioAdaptives, I look forward to the new leadership of James Keener, which will focus more on sales and distribution. I understand that Mr. Keener enjoys a reputation as an innovative Marketer with expertise in helping companies increase Revenues and Profits." Outgoing President Robert Ellis adds, "The company is extremely happy in anticipation of Mr. Keener's strong and varied executive management leadership and innovation, especially in the areas of marketing and sales development and expansion. We wish the New Management Team well in achieving their goals and objectives for BioAdaptives."

"BioAdaptives extends its good wishes and appreciation to both Dr. Jacobs and Mr. Ellis for their many years of dedicated work. The Company fully appreciates the personal and family demands that required their new focus," said Mr. James Keener. "I am honored to be part of BioAdaptives and am excited to get to work applying my extensive experience in operational transformation to another exciting sector."

Mr.Keener adds, "I am committed to leveraging our core strengths and unlocking new opportunities for innovation and growth, aligning with our mission to improve health and wellness through high-quality, research-driven nutritional products; together, we will continue to enhance our product offerings and expand our market footprint."

$BDPT

[Rainer]

https://www.otcmarkets.com/stock/BDPT/news/story?e&id=2866848

[carusso]

Hope so, too!

[stervc]

carusso...

I'm just holding and hoping that the CEO given his qualifications would not be here keeping BDPT current with it SEC filing if he had no plan to eventually move forward.

v/r
Sterling

[carusso]

Ok, thx

[pinkslipjunkie]

I don't know what will happen here...sorry I can't give you a better insight

[carusso]

Care to share your views on the future of this company?

[carusso]

Thanks for posting that…

Does this still have a detectable pulse?

[DK11]

Hopefully INTHEKNOW1 got rid of all his shares coming to an end now.

[LJ-Bodhi]

More dilution with over a billion shares now. More losses, no money, no prospects. Downward trend likely to continue.

[pinkslipjunkie]

It looks like they pulled through on the 10Q.
https://ih.advfn.com/stock-market/USOTC/bioadaptives-pk-BDPT/stock-news/93882024/form-10-q-quarterly-report-sections-13-or-15d

[WorkinGreen]

Aren’t you a sight for sore eyes. Good to see you on board.

[I-Glow]

That is hilarious - they have a new auditor because Borgers is a prohibited service provider.

"SEC Charges Audit Firm BF Borgers with Fraud"

The question is why did BDPT use a fraudulent auditor?

You didn't mention that BDPT is listed as a Shell Risk.

The Securities Counsel Donald Keer doesn't have many reputable clients on the OTC.

IG

[WorkinGreen]

That would be ideal

[starkd748]

Give me no bid .0001s

[DK11]

This will soon go to 3 then 2.

[WorkinGreen]

Thanks stervc

$BDPT

[stervc]

BDPT 8-K New Auditor...

BDPT 8-K New Auditor...

https://www.otcmarkets.com/filing/html?id=17535806&guid=RrQ-k619PyECJth
On May 11, 2024, BioAdaptives’ Board approved the appointment of Boladale Lawal & Co as the Company’s new independent registered PCAOB firm, effective immediately to perform independent audit services for the fiscal year ending December 31,2024 and also the reviews of its quarterly reporting of 2024. Furthermore, Boladale Lawal & Co. will audit the balance sheet of the Company as of December 31, 2023, and the related statements of operations, stockholders’ equity and cash flows for the year then ended. Based upon the audits, Boladale Lawal & Co. will issue a written report on the Company’s financial statements as well.

v/r
Sterling

[Rainer]

http://archive.fast-edgar.com/20240514/AE2ZL62CZ222RZZ2222Q2Z4FI4GCZC228962/

[Tim36]

Knowing this was occurring?

[KeepItRealistic]

$BDPT used 1800 Diagonal Lending, LLC extensively…

U.S. SECURITIES AND EXCHANGE COMMISSION

Litigation Release No. 25995 / May 7, 2024
Securities and Exchange Commission v. Power Up Lending Ltd., et al., No. 1:24-cv-03498 (S.D.N.Y. filed May 7, 2024)
SEC Sues Curt Kramer and Three of His Businesses for Acting as Unregistered Securities Dealers

The Securities and Exchange Commission announced today charges against Curt Kramer of Jericho, New York, and his wholly owned businesses Power Up Lending Ltd., Geneva Roth Remark Holdings, Inc., and 1800 Diagonal Lending, LLC (formerly known as Sixth Street Lending LLC), for operating as unregistered securities dealers.

The SEC's complaint, filed in the United States District Court, Southern District of New York, alleges that since at least January 2018 through at least March 2023, Kramer and his companies engaged in the business of purchasing convertible securities from penny stock issuers, converting those securities into common stock at a large discount from the prevailing market price, and quickly selling the newly issued shares into the market for a profit. The SEC's complaint alleges that the Defendants purchased nearly 2,000 convertible securities from about 325 microcap stock issuers, converted the securities into more than 100 billion newly-issued shares of common stock, rapidly sold the newly issued shares into the market, and generated millions of dollars in revenues and profits. As alleged, Kramer and his companies were not registered as dealers with the SEC or associated with a registered broker-dealer, as their activities required them to do.

The SEC's complaint charges Kramer, Power Up, Geneva Roth, and 1800 Diagonal with violating the dealer registration provision of Section 15(a)(1) of the Securities Exchange Act of 1934 ("Exchange Act"), and also alleges Kramer is liable as a control person of his companies pursuant to Section 20(a) of the Exchange Act. The SEC seeks a permanent injunction, disgorgement of ill-gotten gains plus prejudgment interest, civil penalties, a penny stock bar, and other equitable relief.

The SEC's investigation was conducted by Stephen LeBlanc and supervised by Lisa Deitch and Stacy Bogert. The litigation will be led by Suzanne Romajas, Daniel Lloyd, and Stephen LeBlanc, and supervised by Christopher Bruckmann.

[02opida]

last pr BioAdaptives, Inc. Announces NaturaComplete, an All-In-One Supplement to Optimize Its AI-Based FYO Obesity Management System

[Dark Roast]

You don’t know. Keep Guessing.

[DK11]

Moving very slowly and now quiet.

[Mutat]

This seems to be moving again.

[INTHEKNOW1]

SOMETHING TELLS ME PR COMMETH!